SCOPUS 정보 검색 플랫폼

Volumn 6, Issue 2, 2001, Pages 83-88

Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor

a VA SAN DIEGO HEALTHCARE SYSTEM (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034944610 PISSN: 13596535 EISSN: None Source Type: Journal
DOI: None Document Type: Review

Times cited : (42)

References (22)

1
- 0442268112
- A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
- (1997) New England Journal of Medicine , vol.337 , pp. 725-733
- Hammer, S.M.¹ Squires, K.E.² Hughes, M.D.³ Grimes, J.M.⁴ Demeter, L.M.⁵ Currier, J.S.⁶ Eron J.J., Jr.⁷ Feinberg, J.E.⁸ Balfour H.H., Jr.⁹ Deyton, L.R.¹⁰ Chodakewitz, J.A.¹¹ Fischl, M.A.¹²

2
- 2642709177
- Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
- (1998) New England Journal of Medicine , vol.338 , pp. 853-860
- Palella F.J., Jr.¹ Delaney, K.N.² Moorman, A.C.³ Loveless, M.O.⁴ Fuhrer, J.⁵ Satten, G.A.⁶ Aschman, D.J.⁷ Holmberg, S.D.⁸

3
- 0034685037
- Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel
- (2000) Journal of the American Medical Association , vol.283 , pp. 381-390
- Carpenter, C.C.J.¹ Cooper, D.A.² Fischl, M.A.³ Gatell, J.M.⁴ Gazzard, B.G.⁵ Hammer, S.M.⁶ Hirsch, M.S.⁷ Jacobsen, D.M.⁸ Katzenstein, D.A.⁹ Montaner, J.S.G.¹⁰ Richman, D.D.¹¹ Saag, M.S.¹² Schechter, M.¹³ Schooler, R.T.¹⁴ Vella, S.¹⁵ Yeni, P.G.¹⁶ Volberding, P.A.¹⁷

4
- 0026480950
- Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
- (1992) Antimicrobial Agents & Chemotherapy , vol.36 , pp. 2423-2431
- Schinazi, R.F.¹ McMillan, A.² Cannon, D.³ Mathis, R.⁴ Lloyd, R.M.⁵ Peck, A.⁶ Sommadossi, J.-P.⁷ St Clair, M.⁸ Wilson, J.⁹ Furman, P.A.¹⁰ Painter, G.¹¹ Choi, W.-B.¹² Liotta, C.¹³

5
- 0028877076
- The effect of absolute configuration on the anti-HIV and anti-HBV activity of nucleoside analogues
- (1995) Antiviral Chemistry & Chemotherapy , vol.6 , pp. 345-355
- Furman, P.A.¹ Wilson, J.E.² Reardon, J.E.³ Painter, G.R.⁴

6
- 0029049277
- 524W91: Anti-HIV, anti-hepatitis B virus
- (1995) Drugs of the Future , vol.20 , pp. 761-765
- Painter, G.R.¹ St Clair, M.² Ching, S.³ Noblin, J.⁴ Wang, L.H.⁵ Furman, P.A.⁶

7
- 0030598407
- Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells: Implications for predicting drug hepatotoxicity
- (1996) Biochemical Pharmacology , vol.52 , pp. 1577-1584
- Cui, L.¹ Schinazi, R.F.² Gosselin, G.³ Imbach, J.-L.⁴ Chu, C.K.⁵ Rando, R.F.⁶ Revankan, G.R.⁷ Sommadossi, J.-P.⁸

8
- 0032829089
- Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP
- (1999) The FASEB Journal , vol.13 , pp. 1511-1517
- Feng, J.Y.¹ Shi, J.² Schinazi, R.F.³ Anderson, K.S.⁴

9
- 7344264636
- Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes
- (1992) Antimicrobial Agents & Chemotherapy , vol.36 , pp. 672-676
- Schinazi, R.F.¹ Chu, C.K.² Peck, A.³ McMillan, A.⁴ Mathis, R.⁵ Cannon, D.⁶ Jeong, L.-S.⁷ Beach, J.W.⁸ Choi, W.-B.⁹ Yeola, S.¹⁰ Liotta, D.C.¹¹

10
- 0027379732
- Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro
- (1993) Antimicrobial Agents & Chemotherapy , vol.37 , pp. 2206-2211
- Mathez, D.¹ Schinazi, D.F.² Liotta, D.C.³ Leibowitch, J.⁴

11
- 0027409698
- Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
- (1993) Antimicrobial Agents & Chemotherapy , vol.37 , pp. 875-881
- Schinazi, R.F.¹ Lloyd R.M., Jr.² Nguyen, M.³ Cannon, D.L.⁴ McMillan, A.⁵ Ilksoy, N.⁶ Chu, C.K.⁷ Liotta, D.C.⁸ Bazmi, H.Z.⁹ Mellors, J.W.¹⁰

12
- 0027285372
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
- (1993) Proceedings of the National Academy of Sciences (USA) , vol.90 , pp. 5653-5656
- Tisdale, M.¹ Kemp, S.D.² Parry, N.R.³ Larder, B.A.⁴

13
- 0027373308
- High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
- (1993) Antimicrobial Agents & Chemotherapy , vol.37 , pp. 2231-2234
- Boucher, C.A.B.¹ Cammack, N.² Schipper, P.³ Schuurman, R.⁴ Rouse, P.⁵ Wainberg, M.A.⁶ Cameron, J.M.⁷

14
- 0029965190
- Favorable interaction of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus
- (1996) Biochemical Pharmacology , vol.51 , pp. 731-736
- Bridges, E.G.¹ Dutschman, G.E.² Gullen, E.A.³ Cheng, Y.⁴

15
- 0004597810
- Preclinical safety evaluation of emtricitabine (Coviracil)
- Durban, South Africa, July; Abstract WePeA4058
- (2000) 13th World AIDS Conference
- Grizzle, T.B.¹ Delehanty, J.² Wang, L.H.³ Rousseau, F.S.⁴ Szczech, G.M.⁵

16
- 0004629516
- Preclinical reproductive and developmental safety profile of Coviracil (emtricitabine, FTC), an oxathiolane nucleoside analog for the treatment of HIV and HBV infection
- Philadelphia, Pa., November; Abstract 100211
- (1999) Infectious Diseases Society of America Annual Meeting
- Grizzle, T.¹ Rousseau, F.² Delehanty, J.³ Hart, R.⁴ Walsh, J.⁵ Wang, L.⁶ Schardein, J.⁷ Stump, D.⁸ Tyl, R.⁹ Szczech, G.¹⁰

17
- 29244463261
- Insights into the molecular mechanism of mitochondrial toxicity of antiviral drugs
- Toronto, Canada, September; Abstract P17
- (2000) 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
- Feng, J.Y.¹ Johnson, A.A.² Johnson, K.A.³ Schinazi, R.F.⁴ Anderson, K.S.⁵ Furman, P.A.⁶

19
- 0004603207
- Selection of FTC dose based on viral kinetics and pharmacokinetics in an accelerated clinical trial design
- Geneva, Switzerland, July; Abstract 12208
- (1998) 12th World AIDS Conference
- Kahn, J.¹ Thompson, M.² Mildvan, D.³ Pottage, J.⁴ Shepp, D.⁵ Van der Horst, C.⁶ Delehanty, J.⁷

20
- 0004602110
- A Phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients
- Chicago, Ill., January; Abstract 16
- (1999) 6th Conference on Retroviruses and Opportunistic Infections
- Delehanty, J.¹ Wakeford, C.² Hulett, L.³ Quinn, J.⁴ McCreedy, B.⁵ Almond, M.⁶ Miralles, D.⁷ Rousseau, F.⁸

21
- 33750278542
- Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults: 48-week follow-up of the ANRS 091 trial
- New Orleans, La., September; Abstract 648
- (2000) Infectious Diseases Society of America annual conference
- Molina, J.-M.¹ Rancinan, C.² Ferchal, F.³ Raffi, F.⁴ Rozenbaum, W.⁵ Sereni, D.⁶ Morlat, P.⁷ Perusat, S.⁸ Chene, G.⁹

22
- 0033847883
- Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
- (2000) Journal of Infectious Diseases , vol.182 , pp. 599-602
- Molina, J.-M.¹ Ferchal, F.² Rancinan, C.³ Raffi, F.⁴ Rozenbaum, W.⁵ Sereni, D.⁶ Morlat, P.⁷ Journot, V.⁸ Decazes, J.-M.⁹ Chêne, J.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.